In conclusion, VHL mutations positively correlate with PD-L1 expression in ccRCC and may influence the response to ccRCC patients to anti-PD-L1/PD-1 immunotherapy (25). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.